Baseline demographic and disease characteristics of patients with RA, by registry.
| Characteristics | BioTRAC | OBRI | ||
|---|---|---|---|---|
| Overall | Anti-TNF Nonresponders* | Overall | Anti-TNF Nonresponders* | |
| N (%) | 736 (100.0) | 101 (13.7) ¥ | 640 (100.0) | 115 (18.0) ¥ |
| Age, yrs | N = 684 | N = 96 | N = 640 | N = 115 |
| 56.3 (13.3) | 52.5 (13.5) | 56.4 (12.8) | 55.0 (12.2) | |
| Disease duration, yrs | N = 314 | N = 56 | N = 640 | N = 115 |
| 8.7 (9.0) | 7.4 (8.3) | 9.7 (9.6) | 8.9 (9.0) | |
| Followup duration, mos | 32.5 (34.5) | 20.8 (20.3) | 21.2 (18.1) | 13.1 (11.5) |
| Sex, female, n (%) | N = 706 | N = 97 | N = 640 | N = 115 |
| 535 (75.8) □ | 76 (78.4) □ | 503 (78.6) | 102 (88.7) | |
| ACPA-positive, n (%) | N = 86 | N = 17 | N = 233 | N = 38 |
| 46 (53.5) | 7 (41.2) | 128 (54.9) | 13 (34.2) | |
| DAS28-ESR† | N = 736 | N = 101 | N = 447 | N = 85 |
| 5.8 (1.8) | 5.6 (1.4) | 4.8 (1.4) | 5.2 (1.0) | |
| SJC28 † | N = 736 | N = 101 | N = 546 | N = 100 |
| 10.5 (7.0) | 9.5 (6.8) | 7.1 (4.9) | 7.2 (5.4) | |
| TJC28 † | N = 736 | N = 101 | N = 539 | N = 98 |
| 12.2 (7.9) | 11.2 (7.3) | 7.5 (6.6) | 8.4 (6.8) | |
| PtGA, 0–10 † | N = 732 | N = 101 | N = 493 | N = 94 |
| 6.0 (2.5) | 6.3 (2.4) | 5.2 (2.3) | 5.7 (2.2) | |
| PGA, 0–10 † | N = 733 | N = 100 | N = 463 | N = 85 |
| 6.4 (2.2) | 6.7 (2.0) | 5.7 (2.6) | 6.6 (2.1) | |
| Anti-TNF agent, n (%) | ||||
| Etanercept | – | – | 271 (42.3) | 43 (37.4) |
| Adalimumab | – | – | 148 (23.1) | 28 (24.4) |
| Golimumab | 150 (20.4) | 24 (23.8) | 72 (11.3) | 18 (15.6) |
| Infliximab | 586 (79.6) | 77 (76.2) | 56 (8.8) | 11 (9.6) |
| Certolizumab | – | – | 93 (14.5) | 15 (13.0) |
↵* Defined as physician-reported primary (1ry) and secondary (2ry) nonresponders.
↵¥ Proportions based on overall patients in the respective registry.
↵† Proportions based on total number of patients with available data. Values are mean (SD) unless otherwise specified. RA: rheumatoid arthritis; BioTRAC: Biologic Treatment Registry Across Canada; OBRI: Ontario Best Practices Research Initiative; ACPA: anticitrullinated protein antibodies; DAS28-ESR: 28-joint count Disease Activity Score based on erythrocyte sedimentation rate; SJC28: 28-joint swollen joint count; TJC28: 28-joint tender joint count; PtGA: patient’s global assessment of disease activity; PGA: physician’s global assessment of disease activity; anti-TNF: anti–tumor necrosis factor.